The Home Office has announced that from 1 November cannabis-derived medicinal products will move from Schedule 1 to Schedule 2 to allow clinicians on the General Medical Council (GMC) specialist register to prescribe them. 

Responding to the announcement, Ash Soni, president of the Royal Pharmaceutical Society (RPS) said: “This news will be welcomed by many patients with a range of serious health conditions. The prospect of a future where safe and effective licensed cannabis-based medicines can be prescribed to help relieve suffering is genuinely exciting.”  

He added: “As with any changes to pharmacy practice we will support the profession in navigating the new legislation. We will work with the NHS to help and support specialists in making the right prescribing decisions.”

Over 89 per cent of RPS members agreed that cannabis should be rescheduled to allow research to take place when surveyed earlier this year and the three RPS national pharmacy boards also signed a policy statement supporting this, which was submitted to the Home Office for consideration in June.

Recommended

Devastating toll of migraine

Some 60 per cent of chronic migraine sufferers feel disabled by the condition, 76 per cent feel frustrated missing out o...

Obesity to cause more female cancers than smoking

Obesity is set to overtake smoking as the biggest preventable cause of cancer in women, according to a new Cancer Resear...




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Training Matters's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.